The use of ustekinumab, which targets the subunit p40 of both IL-23 and IL-12, is efficacious in the treatment of IBD, although the role of IL-12, which is normally involved in Th1 differentiation, seems to be marginal in this setting. The gene discussed is IL37; the disease is inflammatory bowel disease.